Evidence map›Paper›PMID 39309503›Full record

ArticleActa pharmaceutica Sinica. B2024

Discovery and evaluation of a novel

Junqi Hu, Yinlong Li, Chenchen Dong, Huiyi Wei, Kai Liao, Junjie Wei, Chunyu Zhao, Ahmad Chaudhary, Jiahui Chen, Hao Xu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. SAR-Guided Scaffold Innovation of Selective VACS medicinal chemistry letters · 2026
    Article
  2. Article
  3. Novel Tetrahydrobenzo[ACS medicinal chemistry letters · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Junqi HuCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Yinlong LiDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Chenchen DongCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Huiyi WeiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Kai LiaoCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Junjie WeiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Chunyu ZhaoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Ahmad ChaudharyDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Jiahui ChenDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Hao XuCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Ke ZhongDepartment of Pharmacy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Lu WangCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Weijian YeCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The arginine-vasopressin (AVP) hormone plays a pivotal role in regulating various physiological processes, such as hormone secretion, cardiovascular modulation, and social behavior. Recent studies have highlighted the V1a receptor as a promising therapeutic target. In-depth insights into V1a receptor-related pathologies, attained through

Indexed as

AutismFluorine 18Kinetic modelingPET imagingPositron emission tomographyRadiolabelingV1a receptorVasopressin

Identifiers

PMID39309503
PMCPMC11413668

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.